VEGFA and eye disorder: Recently, two humanized monoclonal antibodies targeting vascular endothelial growth factor-A (VEGF-A), ranibizumab (Lucentis) and bevacizumab (Avastin) have revolutionized the treatment of eye diseases such as age-related macular degeneration.